Abstracts » Health

Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine

Article Abstract:

Treating patients with Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine (2CdA) may reduce tumor size and relieve symptoms of the disease. Waldenstrom macroglobulinemia is a lymphatic malignancy that primarily affects the elderly and is characterized by weakness, fatigue and bleeding disorders. Of 29 patients with Waldenstrom macroglobulinemia, 17 (59%) experienced significant tumor reduction and marked relief of symptoms. All previously untreated patients went into remission after 2CdA therapy, and three of four patients who had relapsed while off of another form of treatment went into remission. Overall, 40% of the patients who had not responded to previous treatment responded to 2CdA. After an average of seven months of follow-up, only one patient who had responded to 2CdA relapsed. Side effects associated with 2CdA therapy were minimal.

Evaluation, Drug therapy, Macroglobulinemia, Waldenstrom macroglobulinemia, Nucleoside analogs

---

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

Article Abstract:

Patients with chronic lymphocytic leukemia who take fludarabine may have an increased risk of developing infection, especially if they have had other chemotherapy. In a study of 402 patients with this type of leukemia who were taking fludarabine, 58% of those who had other chemotherapy developed infections compared to 34% of those who had never had chemotherapy. Risk factors for infection included previous chemotherapy, severe disease, failure to respond to fludarabine and a poorly functioning immune system.

Health aspects, Infection, Complications and side effects, Risk factors, Cancer patients, Chemotherapy, Fludarabine, Chronic lymphocytic leukemia

---

Some parts © 2012 Advameg, Inc.